SPARC/Sec/SE/2018-19/049 21st December 2018

To
The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051.

BSE Limited
P J Towers,
Dalal street,
Mumbai - 400001

Ref: *Scrip Code: NSE: SPARC; BSE: 532872*

Sub: *Receipt of US FDA Approval of ELEPSIA™ XR 1000mg and ELEPSIA™ XR 1500mg*

Dear Sir/Madam,

Pursuant to regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we are pleased to inform you that U.S. Food and Drug Administration (USFDA) has approved the New Drug Application (NDA) of Elepsia™ XR 1000 mg (levetiracetam 1000 mg) and Elepsia™ XR 1500 mg (levetiracetam 1500 mg). Elepsia™ XR was filed from Sun Pharmaceutical Industries Limited's Halol (Gujarat, India) facility.

SPARC had out-licensed ELEPSIA™ XR to a wholly owned subsidiary of Sun Pharmaceutical Industries Limited in July 2016.

We request you to kindly take the same on record.

Yours faithfully,
For **Sun Pharma Advanced Research Company Limited**

Debashis Dey
Company Secretary